Filing Details

Accession Number:
0001209191-22-017063
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-08 16:13:37
Reporting Period:
2022-03-04
Accepted Time:
2022-03-08 16:13:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
818686 Teva Pharmaceutical Industries Ltd TEVA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1722360 Matthew David Stark C/O Teva Pharmaceutical Industries Ltd.
124 Dvora Hanevi'A St.,
Tel Aviv L3 6944020
Exec. Vp Chief Legal Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2022-03-04 37,939 $0.00 59,319 No 4 M Direct
Ordinary Shares Disposition 2022-03-04 17,008 $7.48 42,311 No 4 S Direct
Ordinary Shares Acquisiton 2022-03-04 13,930 $0.00 56,241 No 4 M Direct
Ordinary Shares Disposition 2022-03-04 6,246 $7.48 49,995 No 4 S Direct
Ordinary Shares Acquisiton 2022-03-05 20,199 $0.00 70,194 No 4 M Direct
Ordinary Shares Disposition 2022-03-07 9,057 $7.37 61,137 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Share Units Disposition 2022-03-04 37,939 $0.00 37,939 $0.00
Ordinary Shares Restricted Share Units Disposition 2022-03-04 13,930 $0.00 13,930 $0.00
Ordinary Shares Restricted Share Units Acquisiton 2022-03-04 127,345 $0.00 127,345 $0.00
Ordinary Shares Restricted Share Units Disposition 2022-03-05 20,199 $0.00 20,199 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
13,931 No 4 M Direct
127,345 No 4 A Direct
60,599 No 4 M Direct
Footnotes
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resourcesand Compensation Committee, the cash value of one ordinary share.
  3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vestingof the restricted share units listed in Table II.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  7. Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.
  8. Restricted share units were granted on March 4, 2019, with 13,930 having vested on each of March 4, 2021 and March 4, 2022, and 13,931 vesting on March 4, 2023.
  9. Restricted share units were granted on March 4, 2022, with 31,836 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 31,837 vesting on March 4, 2026.
  10. Restricted share units were granted on March 5, 2021, with 20,199 having vested on March 5, 2022, 20,199 vesting on each of March 5, 2023 and March 5, 2024, and20,201 vesting on March 5, 2025.